Indaptus Therapeutics, Inc.
INDP
$0.4649
-$0.0151-3.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.33% | -2.49% | 2.36% | -5.77% | 1.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.18% | -5.60% | 5.71% | -0.61% | 9.84% |
| Operating Income | 6.18% | 5.60% | -5.71% | 0.61% | -9.84% |
| Income Before Tax | 2.60% | 1.21% | -7.71% | 1.54% | -7.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.60% | 1.21% | -7.71% | 1.54% | -7.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.60% | 1.21% | -7.71% | 1.54% | -7.68% |
| EBIT | 6.18% | 5.60% | -5.71% | 0.61% | -9.84% |
| EBITDA | 6.18% | 5.60% | -5.71% | 0.61% | -9.85% |
| EPS Basic | 11.67% | 4.51% | -6.28% | 2.82% | -5.91% |
| Normalized Basic EPS | 11.67% | 4.51% | -6.28% | 2.83% | -5.90% |
| EPS Diluted | 11.67% | 4.51% | -6.28% | 2.82% | -5.91% |
| Normalized Diluted EPS | 11.67% | 4.51% | -6.28% | 2.83% | -5.90% |
| Average Basic Shares Outstanding | 11.36% | 4.25% | 1.37% | 1.37% | 1.68% |
| Average Diluted Shares Outstanding | 11.36% | 4.25% | 1.37% | 1.37% | 1.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |